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FoxO transcription factors control development and
longevity in diverse species. Although FoxO regula-
tion via changes in its subcellular localization is well
established, little is known about how FoxO activity
is regulated in the nucleus. Here, we show that the
conserved C. elegans protein EAK-7 acts in parallel
to the serine/threonine kinase AKT-1 to inhibit the
FoxO transcription factor DAF-16. Loss of EAK-7
activity promotes diapause and longevity in a DAF-
16/FoxO-dependentmanner.Whereasakt-1mutation
activatesDAF-16/FoxObypromoting its translocation
from the cytoplasm to the nucleus, eak-7 mutation
increases nuclear DAF-16/FoxO activity without influ-
encing DAF-16/FoxO subcellular localization. Thus,
EAK-7 and AKT-1 inhibit DAF-16/FoxO activity via
distinct mechanisms. Our results implicate EAK-7 as
a FoxO regulator and highlight the biological impact
of a regulatory pathway that governs the activity of
nuclear FoxO without altering its subcellular location.
INTRODUCTION
FoxO transcription factors (TFs) promote life span extension,
stress resistance, and metabolic homeostasis in diverse species
(Accili and Arden, 2004; Arden, 2008; Calnan and Brunet, 2008;
Gross et al., 2008; Partridge and Bru¨ning, 2008). FoxO knockout
mice develop tumors and exhibit abnormalities in glucose
metabolism and bone mineral density (Ambrogini et al., 2010;
Dong et al., 2008; Matsumoto et al., 2007; Paik et al., 2007;
Rached et al., 2010), suggesting that dysregulation of FoxO
TFs may contribute to the pathophysiology of common human
diseases associated with aging, such as cancer, type 2 diabetes,
and osteoporosis. Intriguingly, FoxO3 polymorphisms are asso-
ciated with extreme longevity in humans (Flachsbart et al., 2009;
Li et al., 2009; Willcox et al., 2008). Thus, understanding how
FoxO TFs are regulated has the potential to yield fundamental
insights into both the pathophysiology of human disease as
well as the physiology of normal aging.30 Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc.Activation of the phosphoinositide 3-kinase (PI3K)/Akt
pathway by insulin and IGF-1 signaling (IIS) results in direct phos-
phorylation of FoxO by Akt and its subsequent association with
14-3-3 proteins and nuclear export (Van Der Heide et al.,
2004), whereupon it is targeted for ubiquitin-mediated proteaso-
mal degradation (Huang et al., 2005; Matsuzaki et al., 2003). The
paradigm of FoxO inhibition by IIS first emerged from genetic
analysis in C. elegans, where a conserved IIS pathway controls
life span, stress resistance, and entry into a developmentally
arrested larval stage known as dauer. The C. elegans insulin-
like receptor (InsR), DAF-2 (Kimura et al., 1997), activates the
PI3K AGE-1 (Morris et al., 1996), PDK-1 (Paradis et al., 1999),
and the AGC family kinases AKT-1, AKT-2, and SGK-1 (Hertweck
et al., 2004; Paradis and Ruvkun, 1998). AKT phosphorylation of
the C. elegans FoxO TF DAF-16 promotes its binding to the
14-3-3 protein FTT-2 and subsequent nuclear exclusion (Berdi-
chevsky et al., 2006; Li et al., 2007a). The PI3K/Akt pathway is
antagonized by the C. elegans phosphatase and tensin (PTEN)
ortholog DAF-18 (Gil et al., 1999; Mihaylova et al., 1999; Ogg
and Ruvkun, 1998; Rouault et al., 1999). Reduction of IIS results
in life span extension, increased stress resistance, and constitu-
tive dauer arrest, and these phenotypes are suppressed by DAF-
16/FoxO loss-of-function mutations (Finch and Ruvkun, 2001;
Kenyon, 2005). Thus, DAF-16/FoxO promotes longevity, stress
resistance, and dauer arrest and is inhibited by IIS.
DAF-16/FoxO localizes to the nucleus in daf-2/InsR mutants
(Henderson and Johnson, 2001; Lee et al., 2001; Lin et al.,
2001); however, nuclear localization per se is insufficient for full
DAF-16/FoxO activation, as a DAF-16/FoxO mutant lacking all
AKT phosphorylation sites exhibits constitutive nuclear localiza-
tion but does not promote dauer arrest or longevity (Hertweck
et al., 2004; Lin et al., 2001). Furthermore, although loss-of-func-
tion alleles of daf-18/PTEN and gain-of-function alleles of akt-1
or pdk-1 fully suppress the dauer-constitutive phenotype of
age-1/PI3K null mutants, they weakly suppress dauer arrest
caused by a partial loss-of-function mutation in daf-2/InsR (Gil
et al., 1999; Ogg and Ruvkun, 1998; Paradis et al., 1999; Paradis
and Ruvkun, 1998). These data suggest that a second pathway
acts in parallel to the PI3K/Akt pathway to regulate the activity
of nuclear DAF-16/FoxO (Figure 1A).
To identify genes encoding regulators of nuclear DAF-16/
FoxO activity, we performed a screen for mutants that enhance
the weak dauer arrest phenotype of an akt-1 null mutant (i.e., eak
Figure 1. EAK-7 Acts in Parallel to AKT-1
to Inhibit Dauer Arrest via DAF-16/FoxO
and DAF-12
(A) Schematic of the DAF-2/InsR pathway.
(B and C) daf-16/FoxO null (B) and daf-12 null (C)
mutations suppress the dauer arrest phenotype
of an eak-7 null mutant at 27C on NGM plates
lacking supplemental cholesterol.
(D) Dauer arrest phenotypes of eak-7(mg338) at
25C. The null allele daf-16(mgDf47) was used in
this experiment.
(E) Dauer arrest phenotypes of the null allele
eak-7(tm3188) at 25C.
(F and G) Genetic interactions of eak-7 null muta-
tion with akt-1, akt-2, and sgk-1 null mutations at
25C (F) and 27C (G) on standard NGM plates
containing supplemental cholesterol.
(H) A daf-12 null mutation suppresses the
dauer arrest phenotype of eak-7;akt-1 double
mutants at 25C. All measurements in this figure
represent the mean +SD. See Table S1 for raw
data and numbers of animals scored in each dauer
assay.
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and characterization of eak-7, which encodes a conserved
protein that regulates development, life span, and stress resis-
tance by controlling nuclear DAF-16/FoxO activity.
RESULTS
At 25C, akt-1 null mutants exhibit nuclear enrichment of DAF-
16/FoxO, but do not arrest as dauers (Hu et al., 2006; Zhang
et al., 2008). We mutagenized akt-1 null mutant animals and
identified rare F2 progeny that arrested as dauers at 25
C. eak
mutants were defined as those mutants whose constitutive
dauer arrest phenotype required the presence of the akt-1 muta-
tion (Hu et al., 2006; Zhang et al., 2008). The eak-7 gene is
defined by the missense allele mg338 and the independently iso-
lated deletion allele tm3188, which is a null allele (Figures S1A
and S1B).Cell Metabolism 12,EAK-7 Acts in Parallel to AKT-1
to Regulate Dauer Arrest
daf-2/InsR mutants arrest as dauers at
25C (Gems et al., 1998; Kimura et al.,
1997). In contrast, whereas eak-7 mu-
tants undergo dauer arrest at 27C on
plates lacking supplemental cholesterol
(Figures 1B and 1C), they develop into
adults on standard NGM plates at 25C
(Figures 1D–1F). However, eak-7 muta-
tion strongly enhances dauer arrest in
an akt-1 null mutant (Figures 1D–1F) as
well as in age-1/PI3K and pdk-1 partial
loss-of-function mutants (Figure S1C)
and in daf-2(e1370) mutants (data not
shown). The enhancement of the dauer
arrest phenotype of an akt-1 null mutantby an eak-7 null mutation indicates that EAK-7 acts in parallel
to AKT-1 to regulate dauer arrest.
EAK-7 Acts in the EAK Pathway to Regulate Dauer
Arrest
Four other EAK proteins act in a single pathway in parallel to
AKT-1 to regulate dauer arrest (Hu et al., 2006; Zhang et al.,
2008). To determine whether EAK-7 also acts in this pathway,
we examined the effect of eak-7 mutation on the dauer arrest
phenotype of other eak mutants. eak-7 mutation did not enhance
the dauer arrest phenotype of eak-3, sdf-9/eak-5, or eak-6
mutants (Figure S1D).
Dauer arrest is also regulated by dafachronic acids (DAs), which
are steroid hormone ligands for the nuclear receptor DAF-12
(Motola et al., 2006). Mutations in the DA biosynthetic proteins
DAF-9 and DAF-36 induce dauer arrest (Gerisch et al., 2001; Jia
et al., 2002; Rottiers et al., 2006), and eak-3 mutations enhance30–41, July 7, 2010 ª2010 Elsevier Inc. 31
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et al., 2008). Similarly, eak-7 mutation strongly enhanced the
dauer arrest phenotype of daf-9 and daf-36mutants (Figure S1E).
Taken together, these data suggest that EAK-7 functions in the
same pathway as other EAK proteins in dauer regulation.
EAK-7 Regulates Dauer Arrest via DAF-16/FoxO
IIS and EAK proteins regulate dauer arrest by inhibiting DAF-16/
FoxO activity (Gottlieb and Ruvkun, 1994; Hu et al., 2006; Ohkura
et al., 2003; Vowels and Thomas, 1992; Zhang et al., 2008). To
determine whether EAK-7 inhibits DAF-16/FoxO, we tested
whether dauer arrest phenotypes in eak-7 mutants were daf-
16/FoxO dependent. Dauer arrest phenotypes of eak-7;akt-1
double mutants and eak-7 single mutants were fully suppressed
by a daf-16/FoxO null mutation (Figures 1B, 1D, and 1E). Dauer
arrest in eak-7 single mutants was also suppressed by a gain-
of-function mutation in akt-1 (Paradis and Ruvkun, 1998) and
a loss-of-function mutation in daf-18/PTEN (Ogg and Ruvkun,
1998) (Figure S1F), both of which are predicted to inhibit DAF-
16/FoxO via increased AKT activity. Thus, EAK-7 regulates
dauer arrest by inhibiting DAF-16/FoxO activity.
eak-7Mutation Does Not Enhance Dauer Arrest in akt-2
Mutants
AKT-1, AKT-2, and SGK-1 physically associate with each other
(Hertweck et al., 2004) and are thought to inhibit DAF-16/FoxO
activity by phosphorylating DAF-16/FoxO at canonical Akt/
PKB phosphorylation sites (Hertweck et al., 2004; Lee et al.,
2001; Lin et al., 2001). Since EAK-7 acts in parallel to AKT-1 to
regulate dauer arrest (Figures 1D–1F), we sought to determine
whether EAK-7 also acts in parallel to AKT-2 and/or SGK-1. To
this end, we constructed eak-7;akt-2, akt-1;akt-2, eak-7;sgk-1,
and akt-1;sgk-1 double mutants using the candidate null alleles
akt-2(ok393) (Hertweck et al., 2004) and sgk-1(mg455) (Soukas
et al., 2009). If EAK-7 acts in parallel to AKT-2 or SGK-1, then
eak-7 mutation should enhance the dauer arrest phenotype of
akt-2 or sgk-1 mutants.
sgk-1 mutants did not undergo significant dauer arrest at 25C
or 27C on standard NGM plates containing cholesterol and did
not enhance the dauer arrest phenotype of akt-1 mutants at
either temperature (Figures 1F and 1G). Thus, in agreement
with previous results (Hertweck et al., 2004), SGK-1 plays a minor
role in dauer regulation. sgk-1 mutation weakly enhanced the da-
uer arrest phenotype of eak-7 mutants at both temperatures
(Figures 1F and 1G), suggesting that SGK-1 acts in parallel to
EAK-7.
In contrast, although akt-2 mutants did not arrest as dauers at
25C or 27C (Figures 1F and 1G), akt-2 mutation strongly
enhanced dauer arrest in an akt-1 mutant (Figure S1G), as previ-
ously reported (Oh et al., 2005). In fact, akt-1;akt-2 double
mutants undergo nonconditional dauer arrest and do not recover
(Oh et al., 2005) (Figure S1G and data not shown). Thus, like
eak-7 mutations, akt-2 mutations are strong enhancers of the
dauer arrest phenotype of akt-1 mutants. The severity of the
akt-1;akt-2 double mutant dauer arrest phenotype, i.e., noncon-
ditional constitutive dauer arrest, is similar to that observed in
age-1/PI3K and daf-2/InsR null mutants (Morris et al., 1996; Patel
et al., 2008) and suggests that AKT-1 and AKT-2 constitute the
major dauer regulatory output of IIS.32 Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc.In contrast to eak-7;akt-1 double mutants, which have a strong
dauer arrest phenotype at 25C (Figures 1D–1F), eak-7;akt-2
double mutants did not arrest as dauers at 25C or 27C (Figures
1F and 1G). Thus, eak-7 mutation does not enhance the dauer
arrest phenotype of akt-2 mutants. This result is consistent
with at least two models of EAK-7 action. EAK-7 could act in
the same pathway as AKT-2 to inhibit DAF-16/FoxO activity.
Alternatively, since akt-2 mutation has a relatively modest effect
on DAF-16::GFP nuclear localization in an akt-1 wild-type back-
ground (Hertweck et al., 2004), the amount of DAF-16/FoxO
present in nuclei of eak-7;akt-2 double mutant animals may
be below the threshold necessary for eak-7 mutation to have a
phenotypic effect.
EAK-7 Regulates Dauer Arrest via DAF-12
DAF-12 is required for dauer arrest in all dauer-constitutive
mutants studied to date (Fielenbach and Antebi, 2008; Hu,
2007). Dauer-constitutive phenotypes of eak-7 single mutants
and eak-7;akt-1 double mutants were fully suppressed by a
daf-12 null mutation (Figures 1C and 1H), indicating that EAK-7
promotes reproductive development by inhibiting DAF-12
activity.
EAK-7 Controls Life Span via DAF-16/FoxO
IIS mutants also exhibit DAF-16/FoxO-dependent life span
extension and stress resistance during adulthood (Gems et al.,
1998; Honda and Honda, 1999; Kenyon et al., 1993; Morris
et al., 1996; Murakami and Johnson, 1996; Paradis et al.,
1999). eak-7 mutants also live longer than wild-type animals
(Figures 2A–2F and S2A–S2E and Table S2), and this phenotype
requires daf-16/FoxO (Figures 2B and S2A and Table S2) as well
as the protein phosphatase 4 regulatory subunit SMK-1 (Kim
et al., 2007; Wolff et al., 2006) and the heat shock TF HSF-1
(Hsu et al., 2003) (Figures S2B and S2C and Table S2), both of
which are required for increased longevity in daf-2/InsR mutants.
eak-7 mutants also exhibited DAF-16/FoxO-dependent resis-
tance to ultraviolet, heat, and oxidative stress (Figures S2F–
S2H and Table S2). Thus, EAK-7 controls life span and stress
resistance by inhibiting DAF-16/FoxO activity.
EAK-7 Acts in Parallel to AKT-1 and AKT-2 to Control
Life Span
In contrast to the strong enhancement of dauer arrest in akt-1
mutants caused by eak-7 mutation (Figures 1D–1F), eak-7 muta-
tion enhanced the extended life span phenotype of akt-1
mutants modestly (mean life spans in days ±SD of 24.0 ± 3.3
for akt-1 versus 25.5 ± 4.9 for eak-7;akt-1, p < 0.0001 by the
log rank test) (Figure 2A and Table S2). eak-7 mutation enhanced
the life span extension phenotype of akt-2 mutants to a compa-
rable extent (mean life spans ±SD of 21.8 ± 3.8 for akt-2 versus
25.7 ± 7.4 for eak-7;akt-2, p < 0.0001 by the log rank test)
(Figure 2C and Table S2). akt-1;akt-2 double mutants exhibited
a profound extension of life span compared to akt-1 and akt-2
single mutants (Figure 2G). This is reminiscent of the extreme
longevity of adult age-1/PI3K null mutants (Ayyadevara et al.,
2008) and suggests that as is the case for dauer regulation,
AKT-1 and AKT-2 are the major outputs of IIS in life span control.
Taken together, these results suggest that whereas EAK-7
acts in parallel to AKT-1 to regulate dauer arrest, EAK-7 acts in
Figure 2. Genetic Interactions of eak-7 Mutants in Life Span Control
(A) Life span phenotype of eak-7 null mutants at 25C.
(B) daf-16/FoxO RNAi suppresses life span extension in eak-7 null mutants.
(C) eak-7 null mutation enhances the life span extension observed in akt-2 null mutants.
(D) sgk-1 activity is required for life span extension in eak-7 null mutants.
(E) eak-7 null mutation enhances life span extension of glp-1(e2141) mutants.
(F) Life span extension in eak-7 null mutants does not require eak-3 activity.
(G) akt-1;akt-2 double mutants are extremely long-lived compared to single mutants.
(H) sgk-1 activity is required for life span extension in akt-1 null mutants. See Table S2 for numbers of animals assayed and p values for all life span experiments.
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Notably, the magnitude of the enhancement of akt-1 and akt-2
mutant life span extension phenotypes by eak-7 mutation is
substantially smaller than the effect of eak-7 mutation on the
akt-1 mutant dauer arrest phenotype.
EAK-7 Acts in Parallel to the Germline to Control Life
Span
Germline ablation extends life span by inducing the nuclear
translocation of DAF-16/FoxO in intestinal cells (Berman andKenyon, 2006; Hsin and Kenyon, 1999; Libina et al., 2003).
Thus, one possible explanation for the relatively modest effect
of eak-7 mutation on life span extension in akt-1 and akt-2
mutants (Figures 2A and 2C) compared to its effect on dauer
arrest in akt-1 mutants (Figures 1D–1F) is that in eak-7;akt-1
and eak-7;akt-2 double mutant adult animals, signals from the
germline that are not present in early larvae inhibit DAF-16/
FoxO nuclear translocation. Therefore, we wished to determine
whether eak-7 mutation enhances life span extension in animals
lacking a germline, in which relative concentrations of nuclearCell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc. 33
Figure 3. DAF-16/FoxO Target Gene
Expression in eak-7 Null Mutants
(A–C) sod-3 (A), mtl-1 (B), and dod-3 (C) mRNA
quantification using quantitative RT-PCR on total
RNA from L2 larvae. Measurements represent
the mean +SD.
(D) sod-3 mRNA quantification in adult animals.
(E) sod-3p::GFP expression in various strains. The
anterior of the animal is facing down in all images.
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mutants with glp-1(e2141) animals, which lack a germline
when raised at 25C (Priess et al., 1987). Life span extension
caused by eak-7 mutation was comparable at 20C and 25C
(compare Figures 2C–2F to Figures 2A and 2B, Table S2). The
magnitude of life span extension caused by the glp-1(e2141)
mutation was consistent with previous reports (Berman and
Kenyon, 2006) and greater than that caused by eak-7 mutation
(Figure 2E and Table S2). Strikingly, glp-1;eak-7 double mutants
lived nearly twice as long as glp-1 single mutants (Figure 2E and
Table S2). Thus, EAK-7 acts in parallel to germline signals to
control life span.
SGK-1 Is Required for Life Span Extension
in eak-7 Mutants
Culturing worms on E. coli HT115 that express sgk-1 double-
stranded RNA promotes long life due to a food avoidance
behavior induced by reduction of sgk-1 activity that results in
dietary restriction (Hertweck et al., 2004; Soukas et al., 2009).
In contrast, sgk-1 null mutants are short-lived when cultured
on the standard E. coli OP50 strain (Soukas et al., 2009). To
determine whether SGK-1 is required for life span extension in
eak-7 mutants, we assayed the life spans of eak-7;sgk-1 double
mutants. The double mutant lived slightly longer than sgk-1 single
mutants and substantially shorter than eak-7 single mutants34 Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc.(Figure 2D and Table S2), indicating that
SGK-1 is necessary for life span extension
in eak-7 mutants. Surprisingly, SGK-1
was also required for life span extension
in akt-1 mutants (Figure 2H and Table
S2). Thus, the requirement for SGK-1 in
life span extension is not specific to
eak-7 mutants. SGK-1 may be required
for full DAF-16/FoxO activation in life
span control, or SGK-1 may promote life
span extension independently of DAF-
16/FoxO.
Life Span Extension in eak-7
Mutants Does Not Require Other
EAK Proteins
Although EAK-7 acts in the same pathway
as other EAK proteins to regulate dauer
arrest (Figure S1D), eak-7 mutants are
distinct from other eak mutants in that
they are long lived (Figures 2F, S2D, and
S2E) (Hu et al., 2006; Zhang et al., 2008).
To determine whether the activity of othereak genes is required for life span extension in eak-7mutants, we
performed life span assays on various eak-7;eak double mutants.
Mutations in eak-3, sdf-9/eak-5, and eak-6 did not suppress life
span extension in eak-7 mutants (Figures 2F, S2D, and S2E
and Table S2). Thus, other EAK proteins are not required for life
span extension caused by eak-7 mutation.
EAK-7 Inhibits DAF-16/FoxO Target Gene Expression
To determine whether eak-7 mutation influences DAF-16/FoxO
activity, we assayed endogenous transcript levels of three
DAF-16/FoxO target genes: sod-3, mtl-1, and dod-3 (Murphy
et al., 2003; Oh et al., 2006) (Figures 3A–3D and S3). In early larval
stages, both eak-7 and akt-1 single mutants had increased DAF-
16/FoxO target gene mRNA levels relative to wild-type animals.
akt-1 mutation caused a consistently larger increase than eak-7
mutation did. Strikingly, eak-7;akt-1 double mutants exhibited
a synergistic increase in mRNA levels of all three DAF-16/FoxO
target genes that either was comparable to or exceeded that
observed in daf-2/InsR mutants (Figures 3A–3C). DAF-16/FoxO
target gene expression in eak-7;akt-1 double mutants was
approximately 50- to 100-fold greater than in wild-type animals
and approximately 6- to 8-fold greater than in akt-1 single
mutants (Figures 3A–3C). As expected, DAF-16/FoxO target
gene expression in this context was completely dependent
upon daf-16/FoxO.
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increases in sod-3 mRNA comparable to increases observed in
larvae, adult eak-7;akt-1 double mutant animals did not exhibit
a synergistic increase in sod-3 transcript levels (Figure 3D).
Furthermore, sod-3 transcript levels in adult eak-7;akt-1 double
mutants were substantially lower than those observed in adult
daf-2/InsR mutants (Figure 3D). This difference in DAF-16/
FoxO target gene expression in distinct life stages of eak-7;
akt-1 double mutants is commensurate with the magnitude of
enhancement of akt-1 mutant dauer arrest and life span exten-
sion phenotypes by eak-7 mutation (Figures 1D–1F and 2A)
and may be a consequence of the inhibitory effect of the adult
germline on DAF-16/FoxO activity (Lin et al., 2001).
In order to determine whether EAK-7 regulates DAF-16/FoxO
target gene expression by influencing promoter activity, we
examined the effect of eak-7 mutation on the expression of
a GFP reporter under the control of the sod-3 promoter (Libina
et al., 2003) in early-stage larvae. Whereas mutations ineak-7and
akt-1 alone did not result in substantial changes in sod-3::GFP
expression, eak-7;akt-1 double mutants exhibited a dramatic
increase in GFP expression throughout the animal, relative to
wild-type animals (Figure 3E). These findings are consistent
with the effects of eak-7 and akt-1 mutations on endogenous
DAF-16/FoxO target gene expression (Figures 3A–3C). Thus,
EAK-7 inhibits DAF-16/FoxO target gene transcription, and in
larvae, the effect of eak-7 mutation on DAF-16/FoxO target
gene transcription is magnified in an akt-1 mutant background.
EAK-7 Inhibits Nuclear DAF-16/FoxO Activity
Because eak-7mutation enhances akt-1mutant phenotypes and
DAF-16/FoxO target gene expression more strongly during larval
development than in adulthood (compare Figures 1D–1F to
Figure 2A and Figures 3A to 3D), we explored the mechanism
by which EAK-7 inhibits DAF-16/FoxO activity in larvae. Since
IIS inhibits DAF-16/FoxO by promoting its cytoplasmic seques-
tration (Henderson and Johnson, 2001; Lee et al., 2001; Lin
et al., 2001), we assayed the subcellular localization of a func-
tional DAF-16::GFP fusion protein (Henderson and Johnson,
2001) in various mutant backgrounds (Figure 4A). As expected,
we observed diffuse fluorescence corresponding to cytoplasmic
localization in wild-type animals and increased punctate fluores-
cence corresponding to nuclear localization in akt-1 mutants
(Figure 4A) (Hertweck et al., 2004; Zhang et al., 2008). In contrast
to akt-1 mutants, eak-7 mutant animals exhibited diffuse fluores-
cence indistinguishable from that observed in wild-type animals
(Figure 4A). These results suggest that unlike AKT-1, which
inhibits DAF-16/FoxO by promoting its translocation from the
nucleus to the cytoplasm, EAK-7 inhibits nuclear DAF-16/FoxO
activity without inducing DAF-16/FoxO nuclear exclusion.
To examine in more detail the possibility that EAK-7 inhibits
nuclear DAF-16/FoxO activity, we determined the effect of
14-3-3 protein loss of function on the dauer arrest phenotype
of eak-7 mutants. The 14-3-3 protein FTT-2 binds to AKT-phos-
phorylated DAF-16/FoxO and sequesters it in the cytoplasm,
and reduction of FTT-2 function promotes DAF-16/FoxO nuclear
localization (Berdichevsky et al., 2006; Li et al., 2007a). Since
ftt-2 deletion is lethal (Berdichevsky et al., 2006; Li et al.,
2007a), we inactivated ftt-2 using RNAi. To clarify whether
EAK-7 acts in the same pathway as AKT-2 in DAF-16/FoxO regu-lation (see Figures 1F and 1G), we also tested the effect of ftt-2
RNAi on the dauer arrest phenotype of akt-2 mutants. If EAK-7
and AKT-2 act in the same pathway to regulate DAF-16/FoxO
activity, then ftt-2 RNAi should have the same effect on the dauer
arrest phenotype of both eak-7 and akt-2 mutants.
As expected, ftt-2 RNAi did not induce dauer arrest in wild-
type or akt-1 mutant animals (Figure 4B). Whereas ftt-2 RNAi
strongly promoted dauer arrest in eak-7 mutant animals, it did
not induce dauer arrest in an akt-2 null mutant. Thus, EAK-7
and AKT-2 act in distinct pathways to regulate DAF-16/FoxO
activity. The lack of phenotypic enhancement observed in
eak-7;akt-2 double mutants (Figures 1F and 1G) is likely a conse-
quence of the relatively modest effect of akt-2 mutation on
DAF-16/FoxO nuclear translocation in a wild-type akt-1 back-
ground (Hertweck et al., 2004). Although this result supports
a model whereby EAK-7 inhibits nuclear DAF-16/FoxO activity,
it does not exclude the possibility that EAK-7 may contribute
to DAF-16/FoxO cytoplasmic retention in an FTT-2-independent
manner.
To further investigate this issue, we determined the effect of
eak-7 mutation on dauer arrest in animals expressing a constitu-
tively nuclear DAF-16/FoxO mutant fused to GFP that lacks
all consensus Akt/PKB phosphorylation sites (DAF-16AM) (Lin
et al., 2001). As previously reported (Lin et al., 2001), wild-type
animals expressing DAF-16AM did not arrest as dauers (Fig-
ure 4C). In contrast, eak-7 mutation promoted highly penetrant
dauer arrest in animals expressing DAF-16AM but not in animals
expressing a wild-type DAF-16::GFP transgene (Figure 4C). This
result provides further support for the hypothesis that EAK-7
inhibits nuclear DAF-16/FoxO activity and indicates that the
ability of eak-7mutation to enhance dauer arrest in akt-1mutants
is a function of nuclear enrichment of DAF-16/FoxO caused by
akt-1 mutation as opposed to the dysregulation of other AKT-1
targets, such as SKN-1 and CEP-1/p53 (Quevedo et al., 2007;
Tullet et al., 2008). Furthermore, it demonstrates that EAK-7
inhibition of DAF-16/FoxO activity does not require the canonical
Akt/PKB phosphorylation sites present in wild-type DAF-16/
FoxO.
Thus, EAK-7 inhibits the activity of DAF-16/FoxO that localizes
to the nucleus by virtue of akt-1mutation (Figures 1D–1F, 3A–3C,
and 3E), depletion of FTT-2 activity (Figure 4B), or mutation of its
Akt/PKB phosphorylation sites (Figure 4C).
EAK-7 Reduces Steady-State DAF-16/FoxO Protein
Levels
To further elucidate the mechanism by which EAK-7 inhibits
DAF-16/FoxO activity, we determined the effect of eak-7 muta-
tion on endogenous DAF-16/FoxO transcript and protein levels.
Mutation of eak-7 and akt-1, either alone or in combination, did
not significantly affect daf-16/FoxO mRNA levels (Figure 4D).
Endogenous DAF-16/FoxO protein was undetectable in lysates
from wild-type and eak-7 single mutants (Figure 4E). In contrast,
DAF-16/FoxO was detectable in lysates from akt-1 single
mutants, and eak-7;akt-1 double mutants exhibited a synergistic
increase in DAF-16/FoxO protein levels compared to eak-7 and
akt-1 single mutants (Figure 4E). Increased DAF-16/FoxO protein
levels were also observed in daf-2/InsR mutants (Figure 4E).
Thus, EAK-7 reduces steady-state DAF-16/FoxO protein levels
in akt-1 mutants without influencing daf-16/FoxO mRNA levels.Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc. 35
Figure 4. EAK-7 Regulation of DAF-16/FoxO
(A) An eak-7 null mutation does not affect the subcellular localization of DAF-16::GFP. White arrows denote nuclear fluorescence in akt-1 mutants. The anterior of
the animal is facing right in all images.
(B) ftt-2 RNAi enhances dauer arrest at 25C in an eak-7 null mutant but not in akt-1 or akt-2 null mutants.
(C) An eak-7 null mutation enhances dauer arrest at 25C in animals harboring DAF-16AM, a constitutively nuclear DAF-16/FoxO mutant GFP fusion protein lacking
all canonical Akt/PKB phosphorylation sites.
(D) eak-7 null mutation does not affect endogenous daf-16/FoxO mRNA levels in L2 larvae.
(E) An eak-7 null mutation increases endogenous DAF-16/FoxO protein levels in an akt-1 null mutant. DAF-16/FoxO protein was quantified by anti-DAF-16/FoxO
immunoblot of whole-worm lysates. Anti-ACT-1 immunoblotting was used to confirm equal protein loading. Measurements in Figure 4 represent the mean +SD.
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EAK-7 Regulates Nuclear DAF-16/FoxO ActivityRelative DAF-16/FoxO protein levels in lysates from various
mutants correlated with both the magnitude of dauer arrest
(Figures 1D–1F) as well as relative levels of DAF-16/FoxO target
gene expression in the same mutants (Figures 3A–3C and 3E).
eak-7 Encodes a Conserved Protein
eak-7 encodes a conserved protein with a consensus N-myris-
toylation motif (Farazi et al., 2001) and a TLDc (TBC and LysM
domain-containing) domain (Doerks et al., 2002), the function
of which is obscure (Figures 5A, 5B, S4A, and S4B). The
mg338 allele is a missense mutation in the TLDc domain (Figures
5A, 5B, and S4A). The eak-7(tm3188) null mutation harbors
a deletion that spans the entire first exon and part of the second
exon of K08E7.1 (Figure 5A). The eak-7 gene lies in an operon36 Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc.downstream of hsb-1 (Figure 5A), which encodes a conserved
protein that binds to and inhibits HSF-1 (Satyal et al., 1998).
EAK-7 Is Expressed in Multiple Tissues
To determine the expression pattern and subcellular localization
of EAK-7, we analyzed transgenic animals that expressed an
EAK-7::GFP fusion protein under the control of the hsb-1 operon
promoter (hsb-1p::EAK-7::GFP). This transgene rescued the life
span extension phenotype of an eak-7 null mutant (Figure S5).
GFP was first expressed during embryogenesis (Figure S6A).
At all stages of postembryonic development, transgenic animals
exhibited fluorescence in the pharynx, nervous system, intestine,
body wall muscle, hypodermis, vulva, and a group of cells near
the anus (Figures 5C and S6B–S6G and data not shown). This
Figure 5. eak-7 Gene Structure, Protein Domain Organi-
zation, and Expression Pattern
(A) eak-7 gene structure. eak-7 is the downstream gene in an
operon with hsb-1. The deletion in the eak-7(tm3188) allele begins
249 bp upstream of the eak-7 initiator methionine codon and
deletes portions of exons 1 and 2 of eak-7. The mg338 allele is
a C/T transition that results in a cysteine-to-tyrosine mutation at
amino acid 315 (C315Y).
(B) EAK-7 domain organization. The N-myristoylation motif and
TLDc domain are shown.
(C) hsb-1p::EAK-7::GFP expression pattern in L4 larvae. hsb-1p::
EAK-7::GFP is strongly expressed in the pharynx and nerve ring
(top panels), in the vulva and ventral nerve cord (middle panels),
and in intestinal cells and cells surrounding the anus (bottom
panels). Images were taken at 4003 magnification. The scale
bar is 10 mm.
(D) Subcellular localization ofwild-type EAK-7::GFP (top panels) and
EAK-7::GFP harboring a mutation of glycine 2 to alanine (G2A;
bottom panels) at 10003magnification. The scale bar is 10 mm.
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promoter fusion constructed as part of a high-throughput
analysis of C. elegans gene expression (Hunt-Newbury et al.,
2007). EAK-7::GFP is also expressed in the XXX cells (Fig-
ure S6H), where eak-3, eak-4, sdf-9/eak-5, and eak-6 are specif-
ically expressed (Hu et al., 2006; Ohkura et al., 2003; Zhang
et al., 2008).
Consistent with the presence of an N-myristoylation motif,
EAK-7::GFP localized to the plasma membrane (Figures 5D
and S6H). Mutation of the glycine residue (G2A) that is required
for N-myristoylation (Farazi et al., 2001) resulted in diffuse cyto-
plasmic fluorescence (Figure 5D), suggesting that the motif is
functional. The G2A EAK-7::GFP mutant partially rescued dauer
arrest in eak-7;akt-1 double mutants (data not shown), indicating
that N-myristoylation is not an absolute requirement for EAK-7
function.
EAK-7 Controls Dauer Arrest and Life Span
Nonautonomously
To determine the site of EAK-7 action in the control of dauer
arrest and life span, we generated tissue-specific EAK-7::GFP
expression constructs and tested their ability to rescue eak-7
mutant phenotypes. Since both EAK-7 and DAF-16/FoxO are
expressed in neurons and intestine (Figure 5C) (Henderson and
Johnson, 2001; Lee et al., 2001; Lin et al., 2001), and DAF-16/
FoxO activity in neurons and intestine promotes dauer arrest
and life span extension (Apfeld and Kenyon, 1998; Libina et al.,
2003; Wolkow et al., 2000), we expressed EAK-7::GFP using
neuron (ric-19p)- and intestine (ges-1p)-specific promoters
(Aamodt et al., 1991; Pilon et al., 2000). Since EAK-7 is also
expressed in the XXX cells (Figure S6H) and acts in the same
pathway as other EAK proteins that are expressed specifically
in the XXX cells (Figure S1D) (Hu et al., 2006; Ohkura et al.,
2003; Zhang et al., 2008), we also tested an EAK-7::GFP trans-Cell Megene expressed under the control of the XXX-specific
eak-4 promoter (Hu et al., 2006). Transgenic lines
harboring these constructs exhibited fluorescence
patterns consistent with the reported promoter speci-
ficity (data not shown).XXX- and neuron-specific EAK-7::GFP expression rescued
the dauer arrest phenotype of eak-7;akt-1 mutants, whereas
intestinal EAK-7::GFP expression failed to rescue dauer arrest
(Figures 6A–6C and Table S3). In contrast, expression of
EAK-7::GFP in the XXX cells, neurons, or intestine was sufficient
to rescue the life span extension phenotype of eak-7 mutants
(Figures 6D–6F and Table S4). Thus, similar to DAF-2/InsR
(Apfeld and Kenyon, 1998; Wolkow et al., 2000), EAK-7 acts
nonautonomously to control both dauer arrest and life span.
DISCUSSION
Our results indicate that EAK-7 defines a conserved pathway
that acts in parallel to signals that inhibit DAF-16/FoxO nuclear
translocation (primarily AKT-1 in early larvae and AKT-1, AKT-2,
and the germline in adults) to control DAF-16/FoxO-dependent
dauer arrest and life span extension (Figure 7). Since an eak-7
null mutation promotes dauer arrest in three distinct contexts,
characterized by increases in relative nuclear concentrations
of DAF-16/FoxO (Figures 1, 4B, and 4C), and enhances life
span extension in germline-deficient animals (Figure 2E), which
exhibit increased DAF-16/FoxO nuclear localization (Lin et al.,
2001), we favor a model whereby EAK-7 inhibits the activity of
nuclear DAF-16/FoxO.
The increase in endogenous DAF-16/FoxO protein levels
caused by eak-7 mutation in an akt-1 mutant background
(Figure 4E) suggests that EAK-7 inhibits nuclear DAF-16/FoxO
activity by reducing steady-state DAF-16/FoxO protein levels.
This could occur via regulation of DAF-16/FoxO synthesis or
turnover. Our data suggest that the DAF-16/FoxO E3 ubiquitin
ligase RLE-1 (Li et al., 2007b) and the cullins CUL-5 and CUL-6
(Ghazi et al., 2007) do not mediate potential effects of EAK-7
on DAF-16/FoxO turnover (Figure S7 and data not shown). At
this time, we cannot exclude the possibility that EAK-7 alsotabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc. 37
Figure 6. Rescue of eak-7 Mutant Pheno-
types by Tissue-Specific EAK-7::GFP
Expression
(A–F) Rescue of dauer arrest at 25C in eak-7;akt-1
double mutants (A–C) and rescue of life span
extension in an eak-7 null mutant (D–F) by EAK-7::
GFP transgenes under the control of eak-4 (XXX-
specific; A and D), ric-19 (neuronal; B and E), and
ges-1 (intestinal; C and F) promoters. ‘‘EX’’ and
‘‘NTS’’ denote transgenic animals carrying the
extrachromosomal array and their nontransgenic
siblings, respectively. Measurements represent
the mean +SD. Data are from a single representa-
tive transgenic line. Data from additional lines are
in Tables S3 and S4.
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EAK-7 Regulates Nuclear DAF-16/FoxO Activityinhibits DAF-16/FoxO activity through mechanisms that are
independent of DAF-16/FoxO protein levels.
EAK-7 controls life span and dauer arrest nonautonomously
(Figure 6), as do DAF-2/InsR and DAF-16/FoxO (Apfeld and Ken-
yon, 1998; Libina et al., 2003; Wolkow et al., 2000). Intestinal
EAK-7::GFP expression rescued life span extension but not da-
uer arrest in eak-7 mutants (Figures 6C and 6F), consistent with
the role of intestinal DAF-16/FoxO in life span control (Libina38 Cell Metabolism 12, 30–41, July 7, 2010 ª2010 Elsevier Inc.et al., 2003). Interestingly, expression of
EAK-7::GFP in the XXX cells, where a
DAF-16::GFP fusion protein is not ex-
pressed (Hu et al., 2006), suffices to
rescue both dauer arrest and life span
extension in eak-7 mutants (Figures 6A
and 6D). Thus, EAK-7 may regulate
DAF-16/FoxO activity via both cell-auton-
omous and cell-nonautonomous mecha-
nisms. Since a functional EAK-7::GFP
fusion protein localizes to the plasma
membrane (Figures 5D and S6H), cell-
autonomous regulation of nuclear DAF-
16/FoxO by EAK-7 is likely to be indirect.
The conservation of EAK-7 and IIS
throughout animal phylogeny (Figure S4B)
suggests that mechanisms by which
EAK-7 regulates DAF-16/FoxO activity
may also be conserved in mammals. In
light of recent reports demonstratingthat FoxO TFs are tumor suppressors and critical regulators of
bone mass and glucose homeostasis in mice (Ambrogini et al.,
2010; Dong et al., 2008; Matsumoto et al., 2006; Paik et al.,
2007; Rached et al., 2010), dysregulation of human EAK-7 may
play a role in the pathogenesis of type 2 diabetes, osteoporosis,
and cancer. EAK-7 may also play a role in human longevity
control, as FoxO3 polymorphisms are associated with extreme
longevity in three independent cohorts of long-lived individualsFigure 7. Genetic Model of EAK-7 Function
during Development and Adulthood
(A) During development, EAK-7 acts in parallel to
AKT-1 to inhibit DAF-16/FoxO activity. SGK-1
plays a minor role in dauer regulation.
(B) In adults, EAK-7 acts in parallel to AKT-1,
AKT-2, and the germline to inhibit DAF-16/FoxO
activity. SGK-1 may be required for maximal
DAF-16/FoxO activity.
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EAK-7 Regulates Nuclear DAF-16/FoxO Activity(Flachsbart et al., 2009; Li et al., 2009; Willcox et al., 2008). Thus,
functional human EAK-7 polymorphisms could influence metab-
olism, tumor survival, bone mineral density, and life span based
on their effect on nuclear FoxO activity.
EXPERIMENTAL PROCEDURES
Strains and Reagents
The following strains were used: N2 Bristol (wild-type), daf-2(e1370) (Kimura
et al., 1997), eak-7(mg338), eak-7(tm3188), akt-1(mg306) (Hu et al., 2006),
daf-16(mgDf47) (Ogg et al., 1997), daf-16(mu86) (Lin et al., 2001), akt-2(ok393)
(Hertweck et al., 2004), sgk-1(mg455) (Soukas et al., 2009), daf-12(rh61rh411)
(Antebi et al., 2000), glp-1(e2141) (Priess et al., 1987), eak-3(mg344) (Zhang
et al., 2008), rle-1(tm2447) (Li et al., 2007b), TJ356 (Henderson and Johnson,
2001), CF1553 (Libina et al., 2003), CF1371, and CF1330 (Lin et al., 2001).
Unless otherwise indicated, the akt-1 mutant allele used was mg306, the
eak-7 mutant allele used was tm3188, and the daf-16/FoxO mutant allele
used was mu86. Double and triple mutants were constructed using standard
genetic techniques. Genotypes were confirmed using either restriction frag-
ment length or PCR polymorphisms.
Dauer Arrest Assays
Dauer arrest assays were performed as described (Zhang et al., 2008). 27C
dauer assays were performed using NGM plates with or without supplemental
cholesterol as indicated.
Life Span Assays
Life span assays were performed at 20C or 25C as described (Zhang et al.,
2008). Briefly, L4 larvae were placed onto NGM plates containing 25 mg/ml
fluorodeoxyuridine (FUDR) and 10 mg/ml nystatin that had been seeded with
203 concentrated E. coli OP50. Animals were assayed for viability visually
or with mild prodding. GraphPad Prism (GraphPad Software; La Jolla, CA)
was used for graphing and statistical analysis.
Quantitative RT-PCR
For L2 animals, wild-type and mutant animals grown at 25C were harvested
24 hr after a 2 hr egg lay, and total RNA was prepared from 300–400 animals
per strain using TRIzol (Invitrogen; Carlsbad, CA). For adults, 50 L4 animals
were placed on FUDR/nystatin plates at 25C and harvested 4 days later.
Quantitative PCR primer sequences are available upon request.
sod-3p::GFP and DAF-16::GFP Localization Assays
sod-3::GFP (muIs84) (Libina et al., 2003) and DAF-16::GFP (zIs356) (Hender-
son and Johnson, 2001) were introduced into various mutant backgrounds
and visualized at 2003 magnification immediately after mounting.
RNAi
Feeding RNAi was performed using standard procedures. For dauer assays,
6 cm plates containing NGM + 5 mM IPTG + 25 mg/ml carbenicillin were
spotted with 500 ml of overnight culture of E. coli HT115 harboring either
control L4440 vector or ftt-2 RNAi plasmid. Plates were allowed to dry over-
night at room temperature. Gravid animals cultured on standard NGM plates
containing E. coli OP50 were picked to RNAi plates for egg lays. Dauers
were scored after progeny had been incubated at 25C for 48–60 hr.
For life span assays, 6 cm plates containing NGM + 5 mM IPTG + 25 mg/ml
carbenicillin + 25 mg/ml FUDR + 10 mg/ml nystatin were spotted with 400 ml of
53 concentrated overnight culture of E. coli HT115 harboring either control
L4440 vector or smk-1 RNAi plasmid. Plates were allowed to dry overnight
at room temperature. Young adult animals were picked to plates and scored
for viability as described.
DAF-16AM Dauer Assay
CF1371 and CF1330 (Lin et al., 2001) carry extrachromosomal arrays contain-
ing either a GFP::DAF-16A transgene with all AKT phosphorylation sites
mutated (CF1371) or a wild-type GFP::DAF-16A transgene (CF1330) with the
rol-6 coinjection marker (Lin et al., 2001). Transgenic animals and their non-
transgenic siblings were identified using a fluorescence dissecting micro-scope and/or the Rol phenotype. Measurements represent the percentage
of Rol animals that arrested as dauers.
Immunoblotting
L2 larvae grown at 25C were harvested 24 hr after a 2 hr egg lay and washed
three times in M9 buffer. Protein lysates were prepared by boiling 600–800
animals per strain in sample buffer (Bio-Rad; Hercules, CA). Proteins were
separated by SDS-PAGE, and immunoblots were performed using standard
procedures. Anti-DAF-16/FoxO antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA), anti-actin antibodies from Millipore (Billerica, MA),
anti-mouse-HRP from GE (Piscataway, NJ), and anti-goat-HRP from Jackson
Laboratory (Bar Harbor, ME). The EAK-7 antibody was raised in rabbits against
a peptide corresponding to the last 19 residues of C. elegans of EAK-7
(Proteintech Group, Inc.; Chicago).
Cloning of eak-7
Isolation, mapping, and sequencing of eak-7(mg338) were performed as
described for eak-3 (Zhang et al., 2008).
Transgenes and Transgenic Rescue Experiments
The hsb-1p::EAK-7::GFP translational fusion was generated using overlap
extension PCR (Hobert, 2002). The following fragments were amplified and
fused: a 3391 bp genomic fragment corresponding to nucleotides
6205–9595 of cosmid K08E7 encoding the hsb-1 promoter, a 1884 bp
genomic fragment corresponding to nucleotides 3090–4973 of cosmid
K08E7 that includes the open reading frame of K08E7.1 up to but not including
the translation termination codon, and a DNA fragment containing GFP and the
unc-54 30 UTR that was amplified from pPD95.75 (a gift from Andrew Fire). The
EAK-7::GFP G2A N-myristoylation mutant was also constructed using overlap
extension PCR by incorporating nucleotide changes into the primers, resulting
in mutation of glycine to alanine at residue 2 of EAK-7.
Tissue-specific EAK-7::GFP transgenes contained the same K08E7.1
genomic sequences as the hsb-1p::EAK-7::GFP construct and were also
generated by overlap extension PCR. The following regions were used in place
of the hsb-1 promoter: 1054 nucleotides upstream of the eak-4 start site ampli-
fied from cosmid F53B2 for the XXX-specific construct, 1547 nucleotides
upstream of the ric-19 start site amplified from pJK325 for the neuron-specific
construct, and 2256 nucleotides upstream of the ges-1 start site amplified
from pJK332 for the intestine-specific construct. All fusion products were veri-
fied by restriction digest or sequencing. Fusion PCR products were purified
using the QIAquick PCR Purification Kit (QIAGEN; Venlo, The Netherlands).
Transgenic animals were generated and localization studies performed
as described previously (Zhang et al., 2008). Animals were injected with a
100 ng/ml mixture containing the transgene construct (25 ng/ml), the rol-6
(pRF4) coinjection marker (12.5 ng/ml), and pBluescript. Transgenic animals
were visualized using an Olympus BX61 upright microscope and analyzed
using SlideBook 4.1 digital microscopy software (Intelligent Imaging Innova-
tions, Inc.; Denver, CO). To determine if EAK-7 was expressed in the XXX cells,
hsb-1p::EAK-7::GFP was injected into worms carrying an integrated sdf-
9p::RFP promoter fusion (Hu et al., 2006). Animals were visualized using a
Leica DM6000 confocal microscope and analyzed using Leica LAS AF Version
1.8.2. Animals were mounted on 2% agarose pads in the presence of 10 mM
levamisole or 10 mM sodium azide, visualized, and photographed immediately
after mounting. Transgenic animals and their nontransgenic siblings were
distinguished using a fluorescence dissecting microscope and/or the Rol
phenotype.
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